New drug velzatinib tested for Hard-to-Treat stomach and intestinal tumors

NCT ID NCT07689201

Not yet recruiting Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This phase 2 trial tests the drug velzatinib in people with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to or cannot tolerate several standard treatments. The study aims to see if velzatinib can shrink or control the tumors and how safe it is. Participants receive velzatinib and are monitored for tumor response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: velzatinib (GSK6042981)
What this could lead to: If velzatinib shrinks or controls tumors, it could offer a new treatment option for people with advanced GIST who have run out of standard therapies.
What could go wrong: This is a small, early-phase study (24 participants) with no comparison group. The drug may not work or may cause side effects, and results may not apply to all GIST patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neoplasm gastrointestinal stromal tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTESTINAL NEOPLASMS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.